Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SAP.0b013e31815888f5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epstein-Barr virus infection in patients with MOGAD.
Mult Scler
January 2025
Neurology Unit, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.
Background: Epstein-Barr virus (EBV) infection increases the risk of having multiple sclerosis (MS). Data on adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are lacking.
Objective: To compare EBV serological status in MOGAD versus MS.
[Registers as central real world data source: the experience of the Italian Multiple Sclerosis and Related Disorders Register].
Epidemiol Prev
September 2024
Struttura Tecnico Operativa, Laboratorio di Ricerca per il Coinvolgimento dei Cittadini in Sanità, Dipartimento di Epidemiologia Medica, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano.
Registers collecting data from clinical practice (real world data) have gained increasing interest in recent years in the scientific, administrative, and regulatory fields. The value of longitudinal data collection in deepening knowledge about a specific pathology and its healthcare complexity is increasingly recognized. This article describes the development, organizational structure, and technical characteristics of the Italian Multiple Sclerosis and Related Disorders Register (RISM).
View Article and Find Full Text PDFComparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system.
Front Neurol
June 2024
Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Article Synopsis
- In 2021, ofatumumab received approval for treating relapsing forms of multiple sclerosis (MS), distinguishing itself as the first subcutaneously administered anti-CD20 monoclonal antibody, unlike ocrelizumab, which is given intravenously.
- A study analyzed Individual Case Safety Reports (ICSRs) related to injection reactions (IRRs) for both drugs from the Eudravigilance database between 2021-2023, collecting data on 860 cases, split nearly evenly between ofatumumab (51%) and ocrelizumab (49%).
- The findings indicated that IRRs were more common with ocrelizumab, characterized by infusion-related reactions, whereas ofatumumab was primarily linked
Three Doses of COVID-19 Vaccines: A Retrospective Study Evaluating the Safety and the Immune Response in Patients with Multiple Sclerosis.
J Clin Med
June 2023
Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Since the beginning of the mass immunization of patients with multiple sclerosis (MS), many data on the efficacy and safety of COVID-19 vaccines have been produced. Considering that MS is an autoimmune disease and that some disease-modifying therapies (DMTs) could decrease the antibody response against COVID-19 vaccines, we carried out this retrospective study with the aim to evaluate the safety of these vaccines in terms of AEFI occurrence and the antibody response after MS patients had received the third dose. Two hundred and ten patients (64.
View Article and Find Full Text PDFHumoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
Mult Scler Relat Disord
December 2022
Institute of Experimental Endocrinology and Oncology (IEOS-CNR), Via S. Pansini 5, 80131, Naples 80131, Italy. Electronic address:
Background: It remains unclear how vaccine doses and combinations of vaccination and infection affect the magnitude and quality of immune responses, particularly against novel SARS-CoV-2 variants in subjects with immune-related disorders, such as people with multiple sclerosis (pwMS). Several studies have evaluated the duration of anti-SARS-CoV-2 immune protection in healthy individuals; however clinical data suggest an attenuated short-term humoral response to SARS-CoV-2 vaccines in pwMS receiving disease-modifying therapies (DMTs).
Methods: In this prospective study, we evaluated the humoral response to the third (3rd) BNT162b2 vaccine (booster) dose in a monocentric cohort of pwMS undergoing eight different DMTs, all without previous SARS-CoV-2 infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!